1 / 12

IAC, Melbourne, Room 203-204 Thursday 24 July, 14:30 – 16:00

Access to Innovation: Making Generic Versions of Newer Antiretrovirals Affordable Focusing on middle income countries Leena Menghaney, MSF Access Camapign. IAC, Melbourne, Room 203-204 Thursday 24 July, 14:30 – 16:00 Organised by International AIDS Society. K KL, IAS, 2013, Andrew Hill.

vanna
Download Presentation

IAC, Melbourne, Room 203-204 Thursday 24 July, 14:30 – 16:00

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Access to Innovation: Making Generic Versions of Newer Antiretrovirals AffordableFocusing on middle income countriesLeena Menghaney, MSF Access Camapign IAC, Melbourne, Room 203-204Thursday 24 July, 14:30 – 16:00 Organised by International AIDS Society

  2. KKL, IAS, 2013, Andrew Hill

  3. UTW, 17th Edition 2014

  4. UTW, 17th Edition 2014

  5. Issues in middle income countries • World Bank classification of countries • Affected by TRIPS patent regime • Lack of transparency on prices being paid by governments • Pressure not to use TRIPS flexibilities combined with lack of political will • Left out of geographical scope of voluntary licenses • Lack of negotiation power/case by case basis • Very high prices in middle income countries. • Barriers to benefiting from generic competition

  6. Use of TRIPS Flexibilities • Countries can send out clear message with a few CLs • Reserve IP incentive for new compounds i.e. active ingredients that represent a fresh contribution to the stock of products available for medicinal use • But not all patent applications relate to new compounds. Majority are for existing drugs (new use, new forms and new formulations) • These can be rejected as such inventions that are common knowledge and practice in the pharmaceutical field • Reduce the patent terms by addressing evergreening

  7. First CL in India • NatcoPharma requested for a • CL for the anti-cancer drug • Nexavar(SorafenibTosylate), • patented by Bayer • Not for drug supplied to the • Public sector but actually sold in • The private sector • Granted in March 2012: • Bayer’s import was grossly inadequate to the needs (hardly 2%) • No import in certain years • Price not reasonably affordable to the public. Bayer price 5210USD for 120 tabs for a month; Natco164USD

  8. Generic competition or tiered pricingshort term gain – long term pain

  9. Recommendations • Systematic Data collection on drug prices in middle income countries • Highlighting the problem • Patent Reform in middle income countries (e.g. Argentina) • Challenging the geographical scope of VLs – using it as a ground for a CL • Global Fund should continue supporting middle income countries • Challenging the World Bank classification of countries as not applicable to public health

More Related